Janney Montgomery Scott LLC reduced its stake in shares of Privia Health Group, Inc. (NASDAQ:PRVA – Free Report) by 1.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,582 shares of the company’s stock after selling 791 shares during the period. Janney Montgomery Scott LLC’s holdings in Privia Health Group were worth $1,049,000 as of its most recent SEC filing.
Several other institutional investors have also recently modified their holdings of PRVA. Allspring Global Investments Holdings LLC raised its position in shares of Privia Health Group by 9.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,970 shares of the company’s stock worth $176,000 after purchasing an additional 756 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its holdings in Privia Health Group by 15.9% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 25,378 shares of the company’s stock valued at $497,000 after acquiring an additional 3,487 shares during the last quarter. Quantbot Technologies LP acquired a new position in Privia Health Group in the 1st quarter valued at $196,000. SG Americas Securities LLC acquired a new position in Privia Health Group in the 1st quarter valued at $131,000. Finally, Swiss National Bank raised its holdings in Privia Health Group by 0.8% in the 1st quarter. Swiss National Bank now owns 186,400 shares of the company’s stock valued at $3,652,000 after acquiring an additional 1,400 shares during the last quarter. 94.48% of the stock is currently owned by institutional investors and hedge funds.
Privia Health Group Price Performance
NASDAQ:PRVA opened at $21.20 on Friday. The firm has a 50-day moving average of $18.71 and a two-hundred day moving average of $18.49. The stock has a market cap of $2.54 billion, a P/E ratio of 212.00, a PEG ratio of 5.07 and a beta of 0.76. Privia Health Group, Inc. has a 1-year low of $15.92 and a 1-year high of $24.30.
Insider Buying and Selling at Privia Health Group
Analyst Upgrades and Downgrades
Several brokerages have weighed in on PRVA. Robert W. Baird boosted their price target on Privia Health Group from $23.00 to $24.00 and gave the company an “outperform” rating in a report on Monday, August 26th. Barclays boosted their price target on Privia Health Group from $19.00 to $21.00 and gave the company an “equal weight” rating in a report on Friday, November 8th. Truist Financial upped their price objective on Privia Health Group from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Royal Bank of Canada restated an “outperform” rating and set a $28.00 price objective on shares of Privia Health Group in a report on Wednesday, August 14th. Finally, KeyCorp started coverage on Privia Health Group in a report on Friday, October 11th. They set an “overweight” rating and a $23.00 price objective for the company. Two research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $25.07.
Check Out Our Latest Report on Privia Health Group
Privia Health Group Profile
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
Featured Articles
- Five stocks we like better than Privia Health Group
- Profitably Trade Stocks at 52-Week Highs
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- What is Insider Trading? What You Can Learn from Insider Trading
- Top-Performing Non-Leveraged ETFs This Year
- The 3 Best Fintech Stocks to Buy Now
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.